Navigation Links
Nektar Announces UCB's Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
Date:5/14/2009

Nektar Advanced Polymer Conjugate Technology Used in Cimzia(R) Through Exclusive Nektar-UCB Collaboration

SAN FRANCISCO, Calif., May 14 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) confirmed today UCB's announcement that the US Food and Drug Administration (FDA) has approved Cimzia(R) (certolizumab pegol), the only PEGylated anti-TNFa (Tumor Necrosis Factor alpha), for the treatment of adult patients with moderately to severely active rheumatoid arthritis. Cimzia(R) utilizes Nektar's polymer conjugate technology through an exclusive Nektar-UCB collaboration.

It is estimated that 5 million people suffer from RA globally. In the United States alone, an estimated 1.3 million people have the disease. Prevalence is not split evenly between genders, since women are three times more likely to be affected than men. Although RA can affect people of all ages, the onset of the disease usually occurs between 35-55 years of age.

Under the terms of the agreement between Nektar and UCB, Nektar receives manufacturing revenues during research, clinical development, and commercialization of Cimzia(R). Nektar also receives royalties on end product sales.

About Cimzia(R)

Cimzia(R) is the only PEGylated anti-TNF (Tumor Necrosis Factor). Cimzia(R) has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha. Over the past decade, TNF-alpha has emerged as a major target of basic research and clinical investigation. This cytokine plays a key role in mediating pathological inflammation, and excess TNF-alpha production has been directly implicated in a wide variety of diseases. The U.S. Food and Drug Administration (FDA) has approved Cimzia(R) for reducing signs and symptoms of Crohn's disease and maintaining clinical response
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Nektar Therapeutics to Present at the Deutsche Bank 34th Annual Health Care Conference in Boston
2. Nektar to Announce Financial Results for the First Quarter of 2009 on Wednesday, May 6, 2009, After Close of U.S.-Based Financial Markets
3. Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results
4. Nektar to Announce Financial Results for the Third Quarter of 2008 on Thursday, November 6, 2008 After Close of U.S.-Based Financial Markets
5. Nektar Therapeutics Announces Second Quarter 2008 Results
6. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
7. Nektar Therapeutics Announces First Quarter 2008 Results
8. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
9. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
10. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
11. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... (HealthDay News) -- Unlike children, the vast majority of adults ... at mealtime, according to a new study. This ... not just Americans, researchers from Cornell University revealed. They ... or improve their eating habits make better choices. "If ... stomach," researcher Brian Wansink, director of the Cornell Food ...
(Date:7/25/2014)... 2014 (HealthDay News) -- Although cervical cancers are declining ... to human papillomavirus (HPV) are increasing, a new study ... base of the tongue and tonsils have increased over ... younger than 45, the Canadian researchers report. "The ... younger men and of anal cancer among younger women ...
(Date:7/25/2014)... that controls when genes are switched on or off ... brain to regulate metabolism, UT Southwestern Medical Center researchers ... therapies to treat obesity and diabetes, since the transcription ... appears to influence the body,s sensitivity to insulin ... to the body,s regulation of food intake and sugar ...
(Date:7/25/2014)... NH (PRWEB) July 25, 2014 Innerspire, ... has joined the company as a Creative Enrollment Specialist. ... extensive relationship building skills as well as his accomplished ... of small business clients, and to service the creative ... Additionally, Greg will work with small business owners ...
(Date:7/25/2014)... American Brain Tumor Association (ABTA) today unveiled branding of ... patient and family conference in Chicago. , “This is ... we – the first and now only national organization ... tumor research – extend our reach by engaging volunteers ... our materials and services into the hands of those ...
Breaking Medicine News(10 mins):Health News:Most Adults Are Members of 'Clean Plate Club' 2Health News:Anal, Throat Cancers on the Rise Among Young Adults, Study Finds 2Health News:Manipulating key protein in the brain holds potential against obesity and diabetes 2Health News:Innerspire, LLC Continues National Expansion 2Health News:Innerspire, LLC Continues National Expansion 3Health News:Innerspire, LLC Continues National Expansion 4Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 2Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 3
... Include 24-oz and Convenient 4-oz Travel Size Spray ... PURE ) today announced an agreement ... silver dihydrogen citrate (SDC)-based disinfectant as OneShot Plus(TM) ... Plus product line. OneShot Plus DD eliminates ...
... retire from BoardNATICK, Mass., March 2 Boston Scientific Corporation ... Board of Directors has elected John E. Sununu as a ... as a U.S. Senator from New Hampshire. He was ... Foreign Relations, and he was appointed the Congressional Representative to ...
... no harm -- from TV viewing by young children, , , MONDAY, ... a shelf full of videos claiming to be educationally stimulating for ... wallet. , A new study suggests that watching television won,t ... several hours a day. , "TV, in and of itself, ...
... Officially Launched to Provide Consumers a Free-of-Charge ... from Funeral Homes, Cremation Services and Cemeteries ... http://www.FuneralDecisions.com ) has announced the official launch ... tool for individuals seeking funeral, cremation, and ...
... System Cart Allows Easier Operation and Improved Workflow ... Traxtal Inc., the pioneer and world leader in ... newly designed system cart for the PercuNav interventional ... Booth # 322 of the Society of Interventional ...
... March 2 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. ... today announced that the Company has amended the ... facility with Valens U.S. (formerly Laurus Master Funds). ... agreed to a near-term extension of this facility, ...
Cached Medicine News:Health News:Sterifide Laboratories to Launch 'Powered by SDC' OneShot Plus Disinfectant and Deodorizer 2Health News:Sterifide Laboratories to Launch 'Powered by SDC' OneShot Plus Disinfectant and Deodorizer 3Health News:Sterifide Laboratories to Launch 'Powered by SDC' OneShot Plus Disinfectant and Deodorizer 4Health News:Boston Scientific Announces Election Of John Sununu To Its Board Of Directors 2Health News:Boston Scientific Announces Election Of John Sununu To Its Board Of Directors 3Health News:Boston Scientific Announces Election Of John Sununu To Its Board Of Directors 4Health News:TV Watching Doesn't Fast-Track Baby's Skills 2Health News:TV Watching Doesn't Fast-Track Baby's Skills 3Health News:Taking the Stress Out of Funeral Planning, FuneralDecisions.com Offers Consumers an Innovative Approach 2Health News:Traxtal to Introduce Next-Generation PercuNav System Cart at SIR Annual Scientific Meeting 2Health News:Bioniche Revolving Credit Facility Maturity Date Amended 2
(Date:7/25/2014)... R.I. , July 25, 2014  CVS Caremark ... a conference call on Tuesday, August 5, 2014, at ... its second quarter 2014 financial results. An ... simultaneously through the Investor Relations portion of the CVS ... webcast, visit http://info.cvscaremark.com/investors . This webcast will be ...
(Date:7/25/2014)... Cardinal Health will today name three of ... its prestigious Independent Pharmacy Best Practices Competition, during the ... nation,s largest gatherings of independent pharmacists. ... Ohio , Tennessee ... selected for implementing exceptionally creative methods that demonstrate how ...
(Date:7/25/2014)... York , July 25, 2014 ... Transparency Market Research "Global and China Insulin Market (Rapid-Acting, ... Industry Analysis, Size, Share, Growth, Trends and Forecast (Value ... was valued at USD 19.99 billion in 2012 and ... from 2013 to 2019 to reach USD 32.24 billion ...
Breaking Medicine Technology:Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 2Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 3Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 4Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 5Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 6Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
... The Clariflex® Intraocular Lens is indicated ... years of age or older in whom ... IOL is a third-generation IOL design made ... is designed both to reduce internal reflections ...
... Chamber Lenses: The Bausch & Lomb PMMA Posterior ... for primary implantation for the visual correction of ... older where a cataractous lens has been removed ... to be placed in the ciliary sulcus or ...
... All USIOL lenses are manufactured ... and processes. Perspex CQ UV ... the multi-piece and single piece ... available in both nonphaco and ...
... sterile nonpyrogenic, transparent viscoelastic solution of highly ... mg/ml of high molecular weight (greater than ... physiological saline. In the limit of zero ... (105 Pa s) at 25 C and ...
Medicine Products: